Search

• This is a randomized trial investigating the impact of ePROMs on the patients' perspective on the caregiver. • The use of ePROMs positively influenced the patients' perception of the physician's compassion. • Despite shorter interactions in ePROM based consultations no negative impact was seen in scores for professionalism, empathy and others. Electronic Patient-reported outcome measures (ePROMs) are increasingly used in radiotherapy departments. However, the impact of ePROM integration on patients' perceptions of healthcare providers, particularly in terms of empathy and professionalism, remains unclear. Thus, this study aims to assess the patients' views on healthcare professionals during ePROM-based consultations. In this randomized trial, radiotherapy patients were enrolled and asked to evaluate video vignettes of consultations between a radiation oncologist and a patient. Two scenarios were shown in random order, one vignette portrayed a paper-chart-based clinic visit, and the other a consultation in which ePROMs were implemented. Established questionnaires such as Physician Compassion Questionnaire (PCQ), Jefferson Patient Perception of Physician Empathy (JPP), Physician Professionalism Questionnaire (PPQ) and Global Consultation Rating Scale (GCRS) were used to rate the healthcare professional. The primary endpoint was physician compassion. Between May and August 2022, 152 patients, predominantly with malignancies of the breast, prostate, and brain participated. Patients rated the physician in ePROM-based consultations with higher mean scores for physician compassion compared to paper chart-based ones (36.4 vs. 34.2, p = 0.029). No negative impact of ePROMs was observed in terms of professionalism, global rating or physician empathy. Despite a shorter duration of the visit and reduced eye contact, 63 % of patients ultimately favored ePROM-based consultations. The ePREFERENCE trial shows that the implementation of ePROMs in clinic visits during radiotherapy treatment positively impacts the patients' perception of the physician's compassion. ePROMs can therefore not only be considered a useful tool to improve workflows but are also broadly accepted by patients. [ABSTRACT FROM AUTHOR]

Poster: Physics track: Intra-fraction motion management PO-1654: Markerless liver stereotactic body radiotherapy on a 1.5 T MR-Linac C. Gani, B. Simon, M. Nachbar, A. Stolte, J. Boldt, C. Marks, D. Thorwarth, D. Zips. [Extracted from the article]

Poster: Clinical track: Other PO-1304: The patientÂ's perspective on radiotherapy on a 1.5 T MR-Linac J. Ehlers, C. Gani, C. Marks, A. Stolte, D. Thorwarth, N. Weidner, A. Müller, D. Mönnich, M. Nachbar, O. Dohm, D. Zips, S. Boeke, PO-1304: The patient's perspective on radiotherapy on a 1.5 T MR-Linac. [Extracted from the article]

Debate: This house believes that there is no future for adaptive radiotherapy in EBRT without an MR-linac SP-0631: For the motion rebuttal (there is no future for ART without an MR-linac) C. Gani. [Extracted from the article]

• Multicentric cohort of n = 605 patients treated with definitive chemoradiotherapy for anal cancer. • Overall, T-category, N-category, age and KPS were associated with worse DFS. • In early stage disease, T-category, HIV status, age, performance status and elevated platelets were associated with worse DFS. Prognosis after chemoradiotherapy (CRT) for anal squamous cell carcinoma (ASCC) shows marked differences among patients according to TNM subgroups, however individualized risk assessment tools to better stratify patients for treatment (de-) escalation or intensified follow-up are lacking in ASCC. Patients' data from eight sites of the German Cancer Consortium - Radiation Oncology Group (DKTK-ROG), comprising a total of 605 patients with ASCC, treated with standard definitive CRT with 5-FU/Mitomycin C or Capecitabine/Mitomycin C between 2004–2018, were used to evaluate prognostic factors based on Cox regression models for disease-free survival (DFS). Evaluated variables included age, gender, Karnofsky performance score (KPS), HIV-status, T-category, lymph node status and laboratory parameters. Multivariate cox models were separately constructed for the whole cohort and the subset of patients with early-stage (cT1-2 N0M0) tumors. After a median follow-up of 46 months, 3-year DFS for patients with early-stage ASCC was 84.9%, and 67.1% for patients with locally-advanced disease (HR 2.4, p < 0.001). T-category (HR vs. T1: T2 2.02; T3 2.11; T4 3.03), N-category (HR versus N0: 1.8 for N1-3), age (HR 1.02 per year), and KPS (HR 0.8 per step) were significant predictors for DFS in multivariate analysis in the entire cohort. The model performed with a C-index of 0.68. In cT1-2N0 patients, T-category (HR 2.14), HIV status (HR 2.57), age (1.026 per year), KPS (HR 0.7 per step) and elevated platelets (HR 1.3 per 100/nl) were associated with worse DFS (C-index of 0.7). Classical clinicopathologic parameters like T-category, N-category, age and KPS remain to be significant prognostic factors for DFS in patients treated with contemporary CRT for ASCC. HIV and platelets were significantly associated with worse DFS in patients with early stage ASCC. [ABSTRACT FROM AUTHOR]

While the results of prospective studies support the use of postoperative stereotactic radiotherapy (RT) to the resection cavity (RC) as the standard of care after surgery, there are several issues that need to be investigated such as factors for improving local control, risk of leptomeningeal disease and radiation necrosis. Further, the optimal dose and fractionation is still under debate. The working group "Stereotactic Radiotherapy" of the German Society of Radiation Oncology (DEGRO) analyzed its multi-institutional database with 661 patients who received postoperative stereotactic RT to the RC. Treatment was performed at 13 centers between 2008 and 2021. Patient characteristics, treatment details, and follow-up data including overall survival (OS), local control (LC) were evaluated. Cox Regression and Kaplan-Meier curves with Log-rank Tests were calculated for selected variables. In this retrospective study, overall survival was 61.5% at 1 year, 47.6% at 2 years, and 35.5% at 3 years, and local control was 84.6% at 1 year, 74.8% at 2 years, and 72.8% at 3 years. 96% of patients were treated with hypofractionated stereotactic radiotherapy (HSRT), only 26 patients received single fraction radiosurgery (4%). Prognostic factors associated with overall survival were Karnofsky Performance Status, RPA and GPA class, controlled primary tumor and absence of extracranial metastases, whereas prognostic factor associated with local control was planning target volume (23 mL or less). HSRT is the most common fractionation form in the treatment of RCs in this multicenter analysis. This approach results in excellent OS and LC outcomes. OS in patients with resected brain metastases is mainly influenced by performance status. In regard to local control, RT of large cavities remain a challenge with significantly worse outcome. [ABSTRACT FROM AUTHOR]

Purpose: To validate a nomogram for the prediction of treatment outcomes after preoperative radiochemotherapy and surgery for locally advanced rectal cancer with a cohort of patients treated with additional deep regional hyperthermia. Patients and methods: A total of 86 patients were treated with preoperative radiochemotherapy and deep regional hyperthermia at our institution. For every patient, the 5-year probability for death, distant metastases and local failure based on a previously published nomogram were calculated and patients were divided into three risk groups. Results: Low-lying and clinically lymph node positive tumours were more frequent in the validation cohort. Five-year Kaplan-Meier estimates for overall survival (OS), distant metastases-free survival (DMFS) and local control (LC) were 87.3%, 79.9%, 95.8% (observed) and 75.5%, 71%, 90% (predicted), respectively. Discrimination between low- and high-risk groups was at a significant level for all endpoints. The c-index was 0.81 (OS), 0.67 (DMFS) and 0.92 (LC), respectively. Conclusions: The nomogram showed reasonable performance when deep regional hyperthermia is incorporated into preoperative therapy. The higher than predicted rates seen for OS and DMFS in particular in the high-risk groups warrant further prospective validation and subsequent investigation of the underlying mechanisms. [ABSTRACT FROM AUTHOR]

Poster: Physics track: Quantitative functional and biological imaging PO-1685: Serial DWI in HNC treated on a 1.5 T MRLinac and benchmark to a reference 3 T diagnostic MRscanner S. Böke, R.M. Winter, M. Nachbar, K. Clasen, C. Gani, A. Stolte, J. Boldt, C. Marks, S. Gatidis, K. Nikolaou, D. Zips, D. Thorwarth. [Extracted from the article]

Poster: Clinical track: Other PO-1292: Radiation planning parameters correlate with peripheral immune status during prostate radiotherapy F. Eckert, B. Frey, D. Zips, C. Gani, H. Rammensee, C. Gouttefangeas. [Extracted from the article]

Poster: Clinical track: Breast PO-0966: Partial breast irradiation at the 1.5T MR-Linac: treatment time and electron stream effect C. De Colle, M. Nachbar, D. Mönnich, S. Boeke, C. Gani, N. Weidner, V. Heinrich, J. Winter, S. Tsitsekidis, O. Dohm, D. Thorwarth, D. Zips. [Extracted from the article]

Poster Highlights: Poster highlights 16 RTT: Novel strategies for treatment planning and delivery PH-0487: Analysis of treatment times and workflow at a 1.5 T MR Linac A. Stolte, J. Boldt, C. Marks, C. Gani, M. Nachbar, C. De-Colle, N. Weidner, A. Mueller, D. Thorwarth, D. Zips, S. Boeke. [Extracted from the article]

Radiation pneumonitis (RP) is a serious complication that can occur after thoracic radiotherapy. The goal of this study is to investigate the incidence of RP after radiochemotherapy with intensity modulated radiotherapy (IMRT) in patients with esophageal cancer and correlate this with dose volume histogram (DVH) related parameters. For this purpose, the clinical course of 73 patients was evaluated and irradiation doses to the lungs were extracted from radiotherapy treatment plans. Furthermore, a systematic review on this topic was conducted across PubMed. In our institutional cohort, Common Terminology Criteria for Adverse Events (CTCAE) grade II or higher RP occurred in four patients (5.5%). The systematic review identified 493 titles of which 19 studies reporting 874 patients qualified for the final analysis. No grade IV or V RP after radiochemotherapy with IMRT for esophageal cancer was reported in the screened literature. Grade II or higher RP is reported in 6.6% of the patients. A higher incidence can be seen with increasing values for lung V20. In conclusion, our institutional data and the literature consistently show a low incidence of symptomatic RP after radiochemotherapy in patients with esophageal cancer treated with IMRT. However, efforts should be made to keep the lung V20 below 23% and specific caution is warranted in patients with pre-existing lung conditions. [ABSTRACT FROM AUTHOR]